Arcadia Biosciences, Inc.
RKDA
$4.26
-$0.12-2.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.26M | 5.05M | 4.61M | 4.37M | 4.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.26M | 5.05M | 4.61M | 4.37M | 4.36M |
| Cost of Revenue | 3.07M | 2.87M | 2.20M | 1.98M | 2.01M |
| Gross Profit | 2.19M | 2.18M | 2.41M | 2.39M | 2.35M |
| SG&A Expenses | 9.31M | 9.63M | 8.68M | 8.30M | 7.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.38M | 12.50M | 10.88M | 10.28M | 9.70M |
| Operating Income | -7.13M | -7.46M | -6.27M | -5.91M | -5.34M |
| Income Before Tax | -762.00K | -4.31M | -724.00K | -181.00K | 1.13M |
| Income Tax Expenses | 8.00K | 8.00K | 7.00K | 7.00K | 8.00K |
| Earnings from Continuing Operations | -0.77 | -4.32 | -0.73 | -0.19 | 1.12 |
| Earnings from Discontinued Operations | -1.25M | -2.72M | -5.10M | -6.59M | -8.14M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 0.00 | 0.00 | 5.00K |
| Net Income | -2.02M | -7.04M | -5.83M | -6.78M | -7.02M |
| EBIT | -7.13M | -7.46M | -6.27M | -5.91M | -5.34M |
| EBITDA | -7.05M | -7.34M | -6.12M | -5.68M | -5.08M |
| EPS Basic | -1.48 | -5.16 | -4.28 | -4.98 | -5.16 |
| Normalized Basic EPS | -2.91 | -3.72 | -2.03 | -1.79 | 0.66 |
| EPS Diluted | -1.48 | -5.16 | -4.28 | -4.99 | -5.16 |
| Normalized Diluted EPS | -2.91 | -3.72 | -2.03 | -1.79 | 0.66 |
| Average Basic Shares Outstanding | 5.46M | 5.45M | 5.45M | 5.45M | 5.44M |
| Average Diluted Shares Outstanding | 5.46M | 5.45M | 5.45M | 5.45M | 5.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |